logo
  

Philip Morris To Acquire OtiTopic - Quick Facts

Philip Morris International Inc. (PM) announced its acquisition of OtiTopic, a U.S. respiratory drug development company. OtiTopic has a late-stage inhalable acetylsalicylic acid (ASA) treatment for acute myocardial infarction.

OtiTopic holds several key patents, differentiated intellectual property, and has confirmed a 505(b)2 pathway. With the acquisition of OtiTopic, Philip Morris looks forward to completing the planned ASPRIHALE registration program.

"The acquisition of OtiTopic is an exciting step in PMI's Beyond Nicotine ambitions," said Jacek Olczak, CEO, Philip Morris.

Philip Morris expects the impact of the acquisition on full-year 2021 adjusted diluted earnings per share to be immaterial.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT